Liao et al. reported that a combination of plasma FAPα plus traditional biomarker (CEA, CYFRA211, SCCA) using ELISA could significantly discriminate (AUC = 0.745) ESCC (n = 151, stage I: 29 + stage II: 59 + stage III/IV: 63) from non-malignancy controls (n = 230, healthy: 194 + benign:36) [25]. The gene discussed is FAP; the disease is esophageal squamous cell carcinoma.